Avalo Therapeutics Inc
C6K0
Company Profile
Business description
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Contact
1500 Liberty Ridge Drive
Suite 321
WaynePA19087
USAT: +1 410 522-8707
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
33
Stocks News & Analysis
stocks
Tesla: Shares fall as market disappointed with Cybercab launch event
We think Tesla stock is fairly valued.
stocks
The best global tech stocks to buy
These 12 undervalued technology stocks look attractive today.
stocks
Earnings margins to improve for mining specialist
Premium products drive margins yet shares fully valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.90 | 15.70 | -0.17% |
| CAC 40 | 8,317.98 | 11.83 | 0.14% |
| DAX 40 | 26,007.63 | 1.10 | 0.00% |
| Dow JONES (US) | 52,786.07 | 628.18 | -1.18% |
| FTSE 100 | 10,811.66 | 10.47 | -0.10% |
| HKSE | 25,238.01 | 79.17 | -0.31% |
| NASDAQ | 26,421.41 | 85.58 | -0.32% |
| Nikkei 225 | 65,142.78 | 126.55 | -0.19% |
| NZX 50 Index | 13,819.43 | 26.53 | 0.19% |
| S&P 500 | 7,673.52 | 45.08 | -0.58% |
| S&P/ASX 200 | 8,911.40 | 16.20 | -0.18% |
| SSE Composite Index | 3,953.44 | 12.89 | 0.33% |